Alison Conlin, MD

Articles

Metastatic Triple-Negative Breast Cancer: Unmet Needs and Future Directions in Care

Aditya Bardia, MD, MPH;Alison Conlin, MD

December 5th 2022

Expert oncologists highlight remaining unmet needs in the setting of metastatic triple-negative breast cancer and look toward future evolutions in care.

Interpreting Data From ASCENT: Practical Use of Sacituzumab Govitecan in mTNBC

Aditya Bardia, MD, MPH;Alison Conlin, MD

December 5th 2022

Centering discussion on sacituzumab govitecan use in metastatic triple-negative breast cancer, expert oncologists reflect on results from the phase 3 ASCENT study.

Sacituzumab Govitecan in mTNBC: Results From the ASCENT Study

Aditya Bardia, MD, MPH;Alison Conlin, MD

November 30th 2022

Centering discussion on sacituzumab govitecan use in metastatic triple-negative breast cancer, expert oncologists reflect on results from the phase 3 ASCENT study.

Metastatic Triple-Negative Breast Cancer: An Evolving Treatment Landscape

Aditya Bardia, MD, MPH;Alison Conlin, MD

November 30th 2022

Key opinion leaders Aditya Bardia, MD, MPH, and Alison Conlin, MD, provide a broad view of the current metastatic triple-negative breast cancer treatment landscape.